Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETON NASDAQ:EWTX NASDAQ:NAMS NYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$29.64-4.5%$22.68$13.09▼$32.31$810.79M0.82347,491 shs83,689 shsEWTXEdgewise Therapeutics$34.88-2.0%$31.52$12.15▼$39.96$3.75B0.251.03 million shs290,499 shsNAMSNewAmsterdam Pharma$39.33+12.8%$31.77$16.78▼$42.00$4.52B0.02869,057 shs2.62 million shsRCUSArcus Biosciences$25.21+1.7%$22.93$7.91▼$28.72$3.18B0.871.25 million shs268,532 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals+2.89%+28.61%+23.78%+110.16%+80.66%EWTXEdgewise Therapeutics-3.81%+14.92%+9.48%+22.27%+145.21%NAMSNewAmsterdam Pharma+12.46%+22.02%+2.77%+1.60%+86.02%RCUSArcus Biosciences-4.97%-2.65%+13.04%+17.82%+212.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$29.64-4.5%$22.68$13.09▼$32.31$810.79M0.82347,491 shs83,689 shsEWTXEdgewise Therapeutics$34.88-2.0%$31.52$12.15▼$39.96$3.75B0.251.03 million shs290,499 shsNAMSNewAmsterdam Pharma$39.33+12.8%$31.77$16.78▼$42.00$4.52B0.02869,057 shs2.62 million shsRCUSArcus Biosciences$25.21+1.7%$22.93$7.91▼$28.72$3.18B0.871.25 million shs268,532 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals+2.89%+28.61%+23.78%+110.16%+80.66%EWTXEdgewise Therapeutics-3.81%+14.92%+9.48%+22.27%+145.21%NAMSNewAmsterdam Pharma+12.46%+22.02%+2.77%+1.60%+86.02%RCUSArcus Biosciences-4.97%-2.65%+13.04%+17.82%+212.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 2.40Hold$39.3331.61% UpsideEWTXEdgewise Therapeutics 2.89Moderate Buy$39.6712.13% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.0026.04% UpsideRCUSArcus Biosciences 2.64Moderate Buy$33.1130.96% UpsideCurrent Analyst Ratings BreakdownLatest ETON, EWTX, NAMS, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026RCUSArcus Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $34.005/6/2026EWTXEdgewise Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.005/4/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026EWTXEdgewise Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026RCUSArcus Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026RCUSArcus Biosciences Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$47.004/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/2/2026RCUSArcus Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$37.00 ➝ $41.003/25/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$79.95M10.23$0.01 per share5,816.87$0.98 per share30.50EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/ANAMSNewAmsterdam Pharma$22.50M194.60N/AN/A$5.97 per share6.38RCUSArcus Biosciences$247M12.87N/AN/A$4.17 per share6.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$4.60M-$0.18N/A16.42N/A-5.75%-2.60%-0.66%5/14/2026 (Estimated)EWTXEdgewise Therapeutics-$167.79M-$1.63N/AN/AN/AN/A-31.97%-30.46%N/ANAMSNewAmsterdam Pharma-$203.82M-$1.73N/AN/AN/A-906.22%-26.67%-24.82%N/ARCUSArcus Biosciences-$353M-$3.30N/AN/AN/A-156.36%-68.97%-35.27%N/ALatest ETON, EWTX, NAMS, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10N/AN/AN/A$22.31 millionN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.48-$0.40+$0.08-$0.40$2.14 million$3.04 million5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 million3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 million2/26/2026Q4 2025EWTXEdgewise Therapeutics-$0.43-$0.47-$0.04-$0.47N/AN/A2/25/2026Q4 2025RCUSArcus Biosciences-$1.11-$0.89+$0.22-$0.89$24.94 million$33.00 million2/18/2026Q4 2025NAMSNewAmsterdam Pharma-$0.40-$0.63-$0.23-$0.63$0.92 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton Pharmaceuticals0.831.571.17EWTXEdgewise TherapeuticsN/A19.8519.85NAMSNewAmsterdam PharmaN/A7.887.88RCUSArcus Biosciences0.194.044.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%EWTXEdgewise TherapeuticsN/ANAMSNewAmsterdam Pharma89.89%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals16.49%EWTXEdgewise Therapeutics23.20%NAMSNewAmsterdam Pharma20.84%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2027.36 million22.85 millionOptionableEWTXEdgewise Therapeutics60107.48 million82.55 millionOptionableNAMSNewAmsterdam Pharma4114.97 million91.01 millionOptionableRCUSArcus Biosciences500125.77 million113.57 millionOptionableETON, EWTX, NAMS, and RCUS HeadlinesRecent News About These CompaniesHC Wainwright Expects Higher Earnings for Arcus Biosciences4 hours ago | marketbeat.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Arcus Biosciences (NYSE:RCUS) StockMay 7 at 1:29 PM | marketbeat.comArcus outlines PEAK-1 full enrollment by year-end 2026 with cash runway into 2H 2028May 6 at 12:16 AM | seekingalpha.comArcus Biosciences, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6 at 2:03 PM | seekingalpha.comArcus Biosciences, Inc. (NYSE:RCUS) Q1 2026 Earnings Call TranscriptMay 6 at 8:51 AM | insidermonkey.comArcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call TranscriptMay 6 at 1:01 AM | seekingalpha.comArcus Biosciences (NYSE:RCUS) Issues Earnings ResultsMay 5 at 9:46 PM | marketbeat.comArcus (RCUS) Q1 2026 Earnings Call TranscriptMay 5 at 7:33 PM | finance.yahoo.comArcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue EstimatesMay 5 at 7:10 PM | zacks.comArcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline UpdateMay 5 at 4:05 PM | businesswire.comArcus Biosciences Inc (RCUS) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 5 at 9:31 AM | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Rating Increased to Strong-Buy at Truist FinancialMay 5 at 7:38 AM | marketbeat.comArcus Advances Quemliclustat With Completed Phase 1 Metabolism StudyMay 2, 2026 | tipranks.comApellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?April 29, 2026 | zacks.comArcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseApril 28, 2026 | zacks.comArcus Biosciences (RCUS) to Release Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comArcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For NowApril 27, 2026 | seekingalpha.comArcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option ShiftApril 25, 2026 | finance.yahoo.comArcus Biosciences Announces New Employment Inducement GrantsApril 24, 2026 | businesswire.comArcus Biosciences (NYSE:RCUS) Hits New 1-Year High - Should You Buy?April 23, 2026 | marketbeat.comGilead, Arcus tumble again in TIGIT, triggering 2 trial cullsApril 22, 2026 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETON, EWTX, NAMS, and RCUS Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$29.64 -1.39 (-4.46%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Edgewise Therapeutics NASDAQ:EWTX$34.88 -0.70 (-1.97%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.NewAmsterdam Pharma NASDAQ:NAMS$39.33 +4.48 (+12.85%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Arcus Biosciences NYSE:RCUS$25.21 +0.43 (+1.74%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
